2023
Risk of SARS‐CoV‐2 following joint and epidural corticosteroid injections: A retrospective study
Raju R, Holder E, Dundas M, Liang J, Donham R. Risk of SARS‐CoV‐2 following joint and epidural corticosteroid injections: A retrospective study. Pain Practice 2023, 24: 472-482. PMID: 37994676, DOI: 10.1111/papr.13321.Peer-Reviewed Original ResearchPCR positivity ratesCharlson Comorbidity IndexInjection groupPositivity rateCS injectionsControl groupCorticosteroid injectionSevere comorbiditiesPolymerase chain reaction positivitySARS-CoV-2 PCREpidural corticosteroid injectionsRetrospective chart reviewTertiary care centerCohort of patientsSignificant disease burdenCoronavirus disease 2019 (COVID-19) pandemicSignificant higher rateSARS-CoV-2Disease 2019 pandemicMultivariate regression analysisComorbidity indexPatients 18Chart reviewRetrospective studyImmunosuppressive effects
2022
Changes in the Utilization of Lumbosacral Epidural Injections Between 2010 and 2019
Ratnasamy PP, Gouzoulis MJ, Kammien AJ, Holder EK, Grauer JN. Changes in the Utilization of Lumbosacral Epidural Injections Between 2010 and 2019. Spine 2022, 47: 1669-1674. PMID: 36281568, PMCID: PMC9643603, DOI: 10.1097/brs.0000000000004467.Peer-Reviewed Original ResearchConceptsElixhauser Comorbidity IndexEpidural injectionTransforaminal injectionsSpinal epidural injectionDescriptive epidemiologic studyLumbosacral epidural injectionNumber of injectionsCurrent Procedural Terminology codingCaudal injectionComorbidity indexPatient agePatient characteristicsPearlDiver databaseLumbar pathologyTerms of specialtyInsurance authorizationPractice patternsService utilizationAverage patientEpidemiologic studiesMedicaid coveragePatientsTransforaminalMedicare coverageUtilization trends